

TABLE OF CONTENTS

Chapter #	Title	Page #
	CERTIFICATES	i- ii
	DECLARATION	iii
	PREFACE	iv-v
	ACKNOWLEDGEMENT	vi-viii
	LIST OF TABLES	ix
	LIST OF FIGURES	x-xii
	LIST OF ABBREVIATIONS	xiii-xvi
1	INTRODUCTION	1-14
1.1	NATURAL MEDICINE	1
1.2	SHIKONIN AND ITS SOURCE	1
1.3	ISOLATION AND CHARACTERIZATION	4
1.4	DERIVATIVES OF SHIKONIN	5
1.5	SHIKONIN AS NUTRACEUTICAL	5
1.6	PHARMACOKINETICS AND BIOAVAILABILITY OF SHIKONIN	6
1.7	PHARMACOLOGY OF SHIKONIN	6
1.7.1	Shikonin in Cancer	7
1.7.2	Shikonin in Inflammation	9
1.7.3	Shikonin in Diabetes	11
1.7.4	Shikonin in Other Therapeutic Areas	12
1.8	OBJECTIVE OF THE STUDY	14
2	REVIEW OF LITERATURE	15-46
2.1	SHIKONIN BIOSYNTHESIS	15
2.2	PHARMACOKINETICS AND BIOAVAILABILITY OF	19

Chapter #	Title	Page #
	SHIKONIN	
2.3	PHARMACOLOGY OF SHIKONIN	20
2.3.1	Shikonin and Cancer	20
	2.3.1.1 Apoptotic effect	21
	2.3.1.2 Anti - angiogenic effect	25
2.3.2	Shikonin and Inflammation	27
2.3.3	Shikonin and Metabolic Disorder	31
2.3.4	Shikonin and Cardiovascular Diseases	35
2.3.5	Shikonin and Anti - Hiv Therapy	35
2.3.6	Shikonin and Neuronal Disease	36
2.3.7	Shikonin and Immune Signaling	36
2.3.8	Shikonin and Wound Healing	37
2.3.9	Shikonin and Antimicrobial Effects	37
2.3.10	Shikonin and Pain	38
2.4	<i>IN VITRO</i> ASSAYS	40
2.4.1	Intracellular Calcium Assay	41
2.4.2	cAMP Accumulation Assay	41
2.4.3	FLIPR Membrane Potential Assay	41
2.4.4	Radioligand Binding Assay	41
2.4.5	Chemotaxis Assay	41
2.4.6	ARE - bla HepG2 Reporter Gene Assay	42
2.4.7	Enzyme Inhibition Assay	42
2.4.8	Cell Viability Assay (CellTiter Glo)	42
2.5	<i>IN VIVO</i> MODELS	43
2.5.1	Rat Pinch Pain Model	43
2.5.2	CFA Induced Hyperalgesia Model	43
2.5.3	Formalin Induced Pain Model	43

Chapter #	Title	Page #
2.6	THERAPEUTIC TARGETS IN MULTIPLE DISEASE CLASSES	43
2.6.1	Therapeutic Targets for Pain	44
2.6.2	Therapeutic Targets for Diabetes	44
2.6.3	Therapeutic Targets for Inflammation	45
2.6.4	Therapeutic Targets in Cardiovascular Disorders	45
2.6.5	Therapeutic Targets for Cancer	45
3	MATERIALS AND METHODS	47-74
3.1	MATERIALS	47
3.1.1	Chemicals	47
3.1.2	Glasswares and Plastic wares	47
3.1.3	Instruments	48
3.1.4	Software's and Tools	48
3.2	CELL CULTURE AND RECOMBINANT CELL LINE DEVELOPMENT	48
3.2.1	Cell Culture	49
3.2.2	Cell Freezing and Recovery	49
3.2.3	Molecular Biology	52
	3.2.3.1 RNA preparation	52
	3.2.3.2 Isolation of total RNA	52
	3.2.3.3 DNase treatment	53
	3.2.3.4 Primers	53
	3.2.3.5 cDNA synthesis from RNA by reverse transcription PCR	54
	3.2.3.6 PCR amplification of cDNA	56
	3.2.3.7 Gel extraction and PCR purification	57
	3.2.3.8 Vector and insert preparation	57
	3.2.3.9 Ligation	57

Chapter #	Title	Page #
	3.2.3.10 Bacterial transformation	58
	3.2.3.11 Selection of positive clone	58
	3.2.3.12 Isolation of plasmid DNA	60
3.2.4	Transfection	60
3.2.5	Clonal Selection of Stable Cells	61
3.3	<i>IN VITRO</i> ASSAY	61
3.3.1	Intracellular Ca ²⁺ Mobilization Assay	61
3.3.2	cAMP Accumulation Assay	63
3.3.3	FLIPR Membrane Potential Assay For Ion Channels	64
3.3.4	Enzyme Assays	65
3.3.5	Radioligand Binding Assay	67
3.3.6	ARE - bla HepG2 Reporter Gene Assay	68
3.3.7	Cell Migration Assay	69
3.3.8	CellTiter - Glo Luminescent Cell Viability Assay	70
3.4	<i>IN VIVO</i> ASSAY	72
3.4.1	Animals	72
3.4.2	Pinch Pain Model	72
3.4.3	Complete Freund's Adjuvant (CFA) Induced Mechanical Hyperalgesia Model	73
3.4.4	Formalin Induced Pain Model (FIP)	73
3.5	STATISTICAL ANALYSIS	73
3.5.1	<i>In Vitro</i> Studies	73
3.5.2	<i>In Vivo</i> Studies	74
4	RESULTS	75-106
4.1	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN PAIN PATHWAYS	75
4.1.1	<i>In Vitro</i> Studies	75

Chapter #	Title	Page #
	4.1.1.1 Effect of shikonin in intracellular Ca ²⁺ mobilization assay	75
	4.1.1.2 Effect of shikonin in cAMP accumulation assay	77
	4.1.1.3 Effect of shikonin in FLIPR membrane potential assay for ion channels	78
	4.1.1.4 Effect of shikonin in enzyme inhibition assays:	80
4.1.2	<i>In Vivo</i> Studies	83
	4.1.2.1 Determination of efficacy of shikonin in pinch pain model	83
	4.1.2.2 Determination of efficacy of shikonin in CFA Induced mechanical hyperalgesia model	84
	4.1.2.3 Determination of efficacy of shikonin in formalin induced pain model	87
4.2	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN DIABETES PATHWAY	89
4.3	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN INFLAMMATION PATHWAY	91
4.4	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN CARDIOVASCULAR AREA	100
4.5	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN CANCER	102
4.5.1	Cell Viability Assay	102
4.5.2	Intracellular Calcium Mobilization and Enzyme Assay	104
5	DISCUSSION	107-120
5.1	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN PAIN PATHWAYS.	109
5.2	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN DIABETES PATHWAY	113
5.3	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN INFLAMMATION PATHWAY	114

Chapter #	Title	Page #
5.4	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN CARDIOVASCULAR AREA	11 6
5.5	IDENTIFICATION OF SIGNALING MECHANISM OF SHIKONIN INVOLVED IN CANCER	11 7
6	SUMMARY AND CONCLUSIONS	12 1-12 5
	BIBLIOGRAPGY	12 6-144

ANNEXURE I: Composition of general buffers, salt solutions and media

ANNEXURE III: List of Publications, Conferences and Reprints